Literature DB >> 18832715

Evasion of complement-mediated lysis and complement C3 deposition are regulated by Francisella tularensis lipopolysaccharide O antigen.

Corey D Clay1, Shilpa Soni, John S Gunn, Larry S Schlesinger.   

Abstract

The bacterium Francisella tularensis (Ft) is a potential weapon of bioterrorism when aerosolized. Macrophage infection is necessary for disease progression and efficient phagocytosis by human macrophages requires serum opsonization by complement. Microbial complement activation leads to surface deposition of a highly regulated protein complex resulting in opsonization or membrane lysis. The nature of complement component C3 deposition, i.e., C3b (opsonization and lysis) or C3bi (opsonization only) fragment deposition, is central to the outcome of activation. In this study, we examine the mechanisms of Ft resistance to complement-mediated lysis, C3 component deposition on the Ft surface, and complement activation. Upon incubation in fresh nonimmune human serum, Schu S4 (Ft subsp. tularensis), Fn (Ft subsp. novicida), and LVS (Ft subsp. holarctica live vaccine strain) were resistant to complement-mediated lysis, but LVSG and LVSR (LVS strains altered in surface carbohydrate structures) were susceptible. C3 deposition, however, occurred on all strains. Complement-susceptible strains had markedly increased C3 fragment deposition, including the persistent presence of C3b compared with C3bi, which indicates that C3b inactivation results in survival of complement-resistant strains. C1q, an essential component of the classical activation pathway, was necessary for lysis of complement-susceptible strains and optimal C3 deposition on all strains. Finally, use of Francisella LPS mutants confirmed O Ag as a major regulator of complement resistance. These data provide evidence that pathogenic Francisella activate complement, but are resistant to complement-mediated lysis in part due to limited C3 deposition, rapid conversion of surface-bound C3b to C3bi, and the presence of LPS O Ag.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832715      PMCID: PMC2782685          DOI: 10.4049/jimmunol.181.8.5568

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

Review 1.  Complement escape of human pathogenic bacteria by acquisition of complement regulators.

Authors:  Peter Kraiczy; Reinhard Würzner
Journal:  Mol Immunol       Date:  2006-01       Impact factor: 4.407

Review 2.  Complement driven by conformational changes.

Authors:  Piet Gros; Fin J Milder; Bert J C Janssen
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

Review 3.  Complement evasion by human pathogens.

Authors:  John D Lambris; Daniel Ricklin; Brian V Geisbrecht
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

Review 4.  Complement evasion by bacteria and parasites.

Authors:  K A Joiner
Journal:  Annu Rev Microbiol       Date:  1988       Impact factor: 15.500

5.  Grey variants of the live vaccine strain of Francisella tularensis lack lipopolysaccharide O-antigen, show reduced ability to survive in macrophages and do not induce protective immunity in mice.

Authors:  Gill Hartley; Rosa Taylor; Jo Prior; Sarah Newstead; Paul G Hitchen; Howard R Morris; Anne Dell; Richard W Titball
Journal:  Vaccine       Date:  2005-09-06       Impact factor: 3.641

6.  Complement-mediated host defense in the lung.

Authors:  W T Watford; A J Ghio; J R Wright
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-11       Impact factor: 5.464

7.  Critical role for serum opsonins and complement receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in phagocytosis of Francisella tularensis by human dendritic cells (DC): uptake of Francisella leads to activation of immature DC and intracellular survival of the bacteria.

Authors:  Abdelhakim Ben Nasr; Judith Haithcoat; Joseph E Masterson; John S Gunn; Tonyia Eaves-Pyles; Gary R Klimpel
Journal:  J Leukoc Biol       Date:  2006-07-20       Impact factor: 4.962

8.  Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis.

Authors:  Joann L Prior; Richard G Prior; Paul G Hitchen; Helen Diaper; Kate F Griffin; Howard R Morris; Anne Dell; Richard W Titball
Journal:  J Med Microbiol       Date:  2003-10       Impact factor: 2.472

9.  Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid.

Authors:  J Scott Ferguson; Jeremy J Weis; Jennifer L Martin; Larry S Schlesinger
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

10.  Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

View more
  57 in total

1.  Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization.

Authors:  Meenu Mishra; Matthew S Byrd; Susan Sergeant; Abul K Azad; Matthew R Parsek; Linda McPhail; Larry S Schlesinger; Daniel J Wozniak
Journal:  Cell Microbiol       Date:  2011-11-10       Impact factor: 3.715

2.  Francisella tularensis Schu S4 O-antigen and capsule biosynthesis gene mutants induce early cell death in human macrophages.

Authors:  Stephen R Lindemann; Kaitian Peng; Matthew E Long; Jason R Hunt; Michael A Apicella; Denise M Monack; Lee-Ann H Allen; Bradley D Jones
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

3.  O-antigen-deficient Francisella tularensis Live Vaccine Strain mutants are ingested via an aberrant form of looping phagocytosis and show altered kinetics of intracellular trafficking in human macrophages.

Authors:  Daniel L Clemens; Bai-Yu Lee; Marcus A Horwitz
Journal:  Infect Immun       Date:  2011-12-27       Impact factor: 3.441

4.  Francisella tularensis Schu S4 lipopolysaccharide core sugar and O-antigen mutants are attenuated in a mouse model of tularemia.

Authors:  Jed A Rasmussen; Deborah M B Post; Bradford W Gibson; Stephen R Lindemann; Michael A Apicella; David K Meyerholz; Bradley D Jones
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

5.  Structure-guided investigation of lipopolysaccharide O-antigen chain length regulators reveals regions critical for modal length control.

Authors:  Sergei Kalynych; Xiang Ruan; Miguel A Valvano; Miroslaw Cygler
Journal:  J Bacteriol       Date:  2011-06-03       Impact factor: 3.490

6.  Complement C3 as a Prompt for Human Macrophage Death during Infection with Francisella tularensis Strain SCHU S4.

Authors:  Susan R Brock; Michael J Parmely
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

7.  Francisella acid phosphatases inactivate the NADPH oxidase in human phagocytes.

Authors:  Nrusingh P Mohapatra; Shilpa Soni; Murugesan V S Rajaram; Pham My-Chan Dang; Tom J Reilly; Jamel El-Benna; Corey D Clay; Larry S Schlesinger; John S Gunn
Journal:  J Immunol       Date:  2010-03-26       Impact factor: 5.422

8.  AR-13, a Celecoxib Derivative, Directly Kills Francisella In Vitro and Aids Clearance and Mouse Survival In Vivo.

Authors:  Ky V Hoang; Haley E Adcox; James R Fitch; David M Gordon; Heather M Curry; Larry S Schlesinger; Peter White; John S Gunn
Journal:  Front Microbiol       Date:  2017-09-11       Impact factor: 5.640

9.  Molecular composition of the alveolar lining fluid in the aging lung.

Authors:  Juan I Moliva; Murugesan V S Rajaram; Sabeen Sidiki; Smitha J Sasindran; Evelyn Guirado; Xueliang Jeff Pan; Shu-Hua Wang; Patrick Ross; William P Lafuse; Larry S Schlesinger; Joanne Turner; Jordi B Torrelles
Journal:  Age (Dordr)       Date:  2014-03-03

10.  MiR-155 induction by F. novicida but not the virulent F. tularensis results in SHIP down-regulation and enhanced pro-inflammatory cytokine response.

Authors:  Thomas J Cremer; David H Ravneberg; Corey D Clay; Melissa G Piper-Hunter; Clay B Marsh; Terry S Elton; John S Gunn; Amal Amer; Thirumala-Devi Kanneganti; Larry S Schlesinger; Jonathan P Butchar; Susheela Tridandapani
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.